Jazz Pharmaceuticals (JAZZ) Leases: 2010-2025
Historic Leases for Jazz Pharmaceuticals (JAZZ) over the last 11 years, with Sep 2025 value amounting to $61.2 million.
- Jazz Pharmaceuticals' Leases fell 20.68% to $61.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year decrease of 20.68%. This contributed to the annual value of $53.6 million for FY2024, which is 18.00% down from last year.
- Latest data reveals that Jazz Pharmaceuticals reported Leases of $61.2 million as of Q3 2025, which was down 2.98% from $63.1 million recorded in Q2 2025.
- In the past 5 years, Jazz Pharmaceuticals' Leases ranged from a high of $149.3 million in Q2 2021 and a low of $49.2 million during Q1 2025.
- Over the past 3 years, Jazz Pharmaceuticals' median Leases value was $65.0 million (recorded in 2023), while the average stood at $64.9 million.
- Per our database at Business Quant, Jazz Pharmaceuticals' Leases slumped by 47.50% in 2022 and then increased by 18.64% in 2024.
- Jazz Pharmaceuticals' Leases (Quarterly) stood at $86.6 million in 2021, then declined by 15.31% to $73.3 million in 2022, then decreased by 10.89% to $65.3 million in 2023, then declined by 18.00% to $53.6 million in 2024, then dropped by 20.68% to $61.2 million in 2025.
- Its last three reported values are $61.2 million in Q3 2025, $63.1 million for Q2 2025, and $49.2 million during Q1 2025.